Overview / Abstract: |
Target Audience The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate. Activity Overview Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variables. This along with the availability of novel therapies and accumulating evidence can make it difficult for clinicians to select appropriate therapy for individual patients. This accredited program discusses patient cases, applicable data, and management strategies in order to facilitate care for patients across the MM disease continuum. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Translate patient-specific factors, risk stratification, and treatment history into personalized treatment plans for patients with R/R MM |
Expiration |
Dec 23, 2022 |
Format |
Online |
Credits / Hours |
2.0 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty FACULTY_NAME FACULTY_NAME FACULTY_NAME FACULTY_NAME FACULTY_NAME |
Sponsors / Supporters / Grant Providers |
Amgen, Inc., Karyopharm Therapeutics, Legend Biotech USA, Inc., Oncopeptides, Sanofi Genzyme, Secura Bio, Inc., and Takeda Oncology. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Multiple Myeloma Free CE CME |